Solid Tumors Stocks List Ranked for 2024 | NYSE,

Symbol	Grade	Name	% Change
LGND	A	Ligand Pharmaceuticals Incorporated	11.12
ACLX	A	Arcellx, Inc.	6.65
INCY	A	Incyte Corporation	1.72
AVBP	B	ArriVent BioPharma, Inc.	2.06
ARGX	B	argenx SE	0.42
REPL	B	Replimune Group, Inc.	-3.86
KYMR	B	Kymera Therapeutics, Inc.	0.24
CNTA	B	Centessa Pharmaceuticals plc	0.94
MRUS	B	Merus N.V.	2.58
INBX	C	Inhibrx, Inc.	2.06

Symbol	Grade	Name	Weight
IDNA	B	iShares Genomics Immunology and Healthcare ETF	11.15
CANC	C	Tema Oncology ETF	10.63
FBT	A	First Trust Amex Biotech Index Fund	7.2
BBH	D	Market Vectors Biotech ETF	6.79
EWK	D	iShares MSCI Belgium Capped Investable Market Index Fund	6.71

Compare ETFs

Compare CANC to BBH Compare CANC to EWK Compare IDNA to FBT

Date	Stock	Title
Nov 7	LGND	Ligand: Q3 Earnings Snapshot
Nov 7	LGND	Ligand Pharmaceuticals beats Q3 top and bottom line estimates
Nov 7	LGND	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Nov 7	ACLX	Arcellx price target raised to $106 from $81 at Morgan Stanley
Nov 7	ACLX	Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Nov 6	MRUS	Merus to Present at Upcoming Investor Conferences
Nov 6	LGND	Ligand Pharmaceuticals Q3 2024 Earnings Preview
Nov 6	ARGX	Peering Into argenx's Recent Short Interest
Nov 6	ACLX	Navigating 7 Analyst Ratings For Arcellx
Nov 6	INCY	Bank of America Turns Bullish on These 2 Lesser-Known Stocks
Nov 5	MRUS	Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 5	ARGX	Why Argenx (ARGX) Might be Well Poised for a Surge
Nov 5	INBX	Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform
Nov 5	ACLX	Arcellx issues updates on anito-cel clinical trials
Nov 5	ACLX	Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
Nov 5	ACLX	Cancer cell therapy from Arcellx, Gilead shows promise in early data
Nov 5	KYMR	Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Nov 5	MRUS	Merus says FDA extended review period for cancer drug
Nov 5	MRUS	Merus Receives FDA extension of PDUFA for zenocutuzumab
Nov 5	INCY	Syndax agrees funding with Royalty Pharma for Niktimvo US sales

Solid Tumors: Solid tumors are masses of abnormal cells that form when cells in the body divide and grow uncontrollably. They are usually found in the organs, but can also form in the tissues of the body. Solid tumors can be benign (non-cancerous) or malignant (cancerous).